Denali Capital Acquisition Corp. Files 8-K on Shareholder Vote

TL;DR

Denali Capital Acquisition Corp. is holding a shareholder vote on Sept 3rd, expect news soon.

AI Summary

Denali Capital Acquisition Corp. filed an 8-K on September 4, 2025, reporting on a submission of matters to a vote of security holders on September 3, 2025. The company, incorporated in the Cayman Islands with its principal executive offices in New York, NY, is involved in the Pharmaceutical Preparations industry.

Why It Matters

This filing indicates a significant corporate event where Denali Capital Acquisition Corp. is seeking approval from its shareholders, which could lead to a merger, acquisition, or other major strategic decision.

Risk Assessment

Risk Level: medium — Filings related to shareholder votes often precede significant corporate actions like mergers or acquisitions, which carry inherent risks and uncertainties.

Key Numbers

• 001-41351 — SEC File Number (Identifies the company's filing history with the SEC.)
• 98-1659463 — IRS Employer Identification No. (Tax identification number for the company.)

Key Players & Entities

• Denali Capital Acquisition Corp. (company) — Registrant
• September 3, 2025 (date) — Date of earliest event reported
• September 4, 2025 (date) — Filing date
• 437 Madison Avenue, New York, NY 10022 (location) — Business Address

FAQ

Key Financial Figures

• $0.0001 — nt Class A ordinary shares, par value $0.0001 per share DNQAF OTCQB Warrants, e
• $11.50 — ordinary share at an exercise price of $11.50 per share DNQWF OTCQB Indicate by

Filing Documents

• ea0255814-8k_denali.htm (8-K) — 63KB
• 0001213900-25-084180.txt ( ) — 278KB
• dnqwf-20250903.xsd (EX-101.SCH) — 4KB
• dnqwf-20250903_def.xml (EX-101.DEF) — 27KB
• dnqwf-20250903_lab.xml (EX-101.LAB) — 37KB
• dnqwf-20250903_pre.xml (EX-101.PRE) — 25KB
• ea0255814-8k_denali_htm.xml (XML) — 7KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On September 3, 2025, Denali Capital Acquisition Corp. (the "Company") held an extraordinary general meeting of shareholders (the "Meeting"). The record date for the determination of shareholders entitled to vote at the Meeting was August 12, 2025. As of the record date, there were 553,739 Class A ordinary shares and 2,062,500 Class B ordinary shares outstanding and entitled to vote. A total of 2,461,469 shares were present in person or by proxy, representing approximately 94.08% of the shares entitled to vote, which constituted a quorum. At the Meeting, each of the proposals and sub-proposals described below was approved by the Company's shareholders. The final voting results for the proposals and sub-proposals submitted to a vote of the Company's shareholders at the Meeting are set forth below. No broker non-votes occurred with respect to any proposal. Proposal 1 To approve, as an ordinary resolution, the Agreement and Plan of Merger, dated as of August 30, 2024 (as amended on April 16, 2025 and July 22, 2025, the "Merger Agreement"), by and among Denali, Denali Merger Sub Inc., and Semnur Pharmaceuticals, Inc. ("Semnur"), and the transactions contemplated thereby (the "business combination"). For Against Abstain 2,461,469 0 0 Proposal 2 To approve, as a special resolution, Denali's continuation out of the Cayman Islands and domestication into the State of Delaware as a corporation (the "domestication"), including approval of the Amended and Restated Certificate of Incorporation of Semnur Pharmaceuticals, Inc. and the Amended and Restated Bylaws of Semnur Pharmaceuticals, Inc., each to be effective under Delaware law prior to the effectiveness of the merger contemplated by the Merger Agreement, and the change of registered office to 251 Little Falls Drive, Wilmington, Delaware 19808, effective upon the domestication. For Against Abstain 19,853,968 1 0 Proposal 3 To

View Full Filing

View this 8-K filing on SEC EDGAR